【摘要】 目的:探讨选择性表皮生长因子受体抑制剂易瑞沙(IRESSA)治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效及不良反应。方法:对既往化疗失败或不能耐受拒绝化疗的晚期NSCLC患者23例,单药IRESSA250mg,口服,每日1次,服用至病情进展或出现不可耐受的不良反应。患者分别在治疗后30、90d对其疗效及不良反应进行观察统计。结果:23例中22例可评价疗效,其中CR1例,PR6例,SD10例,PD5例,有效率31·8%(7/22),患者疾病控制率(CR+PR+SD)77·3%(17/22)。治疗后30d肿瘤相关症状缓解率为73·9%(17/23)。Karnofsky评分,治疗前总分数900,人均39·1;治疗后总分数1380,人均60;治疗前后比较差异有统计学意义,t=-3·18,P=0·004。常见不良反应为腹泻和皮肤改变,Ⅳ级占4·3%(1/23)。结论:IRESSA单药对化疗失败或不能耐受的晚期NSCLC疗效确切,改善症状明显,用药方便,不良反应轻。更多还原

【Abstract】 OBJECTIVE:To evaluate the clinical efficacy and adverse reactions of the selective epidermal growth factor receptor (EGFR) inhibitor in the treatment of advanced non-small-cell lung cancer (NSCLC). METHODS: Twenty-three patients with failure of previous chemotherapy regimens or treatment intolerance received IRESSA as a single agent treatment with 250mg daily dose until disease progressed or intolerant side effects occurred. The efficacy and side effects were evaluated 30 days and 90 days after treatment. RESULTS: Twenty-two of 23 cases could be assessed, 1 case had complete response(CR),6 cases had a partial response (PR),10 cases had stabledisease (SD), 5 cases had a progression of disease (PD);the response rate was 31.8%;and the disease control rate (CR+PR+SD) was 77.3%(17/22). The release rate of disease-related symptoms 30 days after treatment was 73.9%(17/23). The overall Karnofsky scores of patients before and after treatment were 900 and 1 380, respectively, and the mean scores of that were 39.1 and 60.0, respectively, (t=(-3.18), P=0.004). Adverse events were diarrhea and rash, with Ⅳ adverse reactions 4.3%(1/23). CONCLUSION: These initial study indicates that the efficacy of IRESSA, as a single agent, in the treatment of NSCLC undergoing failed or intolerant chemotherapy is confirmed, with the benefit of improved symptoms, convenient administration and mild adverse events.更多还原